Bayer AG - Product Pipeline Review - 2016

  • ID: 3743722
  • Company Profile
  • 250 pages
  • Global Markets Direct
  • Bayer AG
1 of 4
Bayer AG - Product Pipeline Review - 2016

Summary

‘Bayer AG - Product Pipeline Review - 2016’, provides an overview of the Bayer AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bayer AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Bayer AG
- The report provides overview of Bayer AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Bayer AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Bayer AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bayer AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bayer AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Introduction

Report Coverage

Bayer AG Snapshot

Bayer AG Overview

Key Information

Key Facts

Bayer AG - Research and Development Overview

Key Therapeutic Areas

Bayer AG - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Bayer AG - Pipeline Products Glance

Bayer AG - Late Stage Pipeline Products

Bayer AG - Clinical Stage Pipeline Products

Bayer AG - Early Stage Pipeline Products

Bayer AG - Unknown Stage Pipeline Products

Bayer AG - Drug Profiles

aflibercept

dienogest

Kovaltry

(candesartan cilexetil + nifedipine)

amikacin sulfate

ciprofloxacin hydrochloride

copanlisib hydrochloride

damoctocog alfa pegol

finerenone

nifurtimox

radium Ra 223 dichloride

regorafenib

rivaroxaban

tedizolid phosphate

(anastrozole + levonorgestrel)

anetumab ravtansine

BAY-1067197

BAY-1142524

molidustat

refametinib

riociguat

roniciclib

vericiguat

vilaprisan

sorafenib tosylate

BAY sGCstim

BAY-1082439

BAY-1093884

BAY-1112054

BAY-1125976

BAY-1128688

BAY-1129980

BAY-1143269

BAY-1143572

BAY-1161909

BAY-1163877

BAY-1179470

BAY-1187982

BAY-1213790

BAY-1214784

BAY-1217389

BAY-1251152

BAY-1862864

Drug for Diabetic Foot Ulcer

Monoclonal Antibodies for Oncology

Monoclonal Antibody Conjugate to Target CD22 for Hematological Cancers

Monoclonal Antibody for Undisclosed Indication

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis

Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders

Small Molecule to Inhibit Kinase for Inflammation and Oncology

BAY sGCact

BAY-1001931

BAY-1024767

BAY-1436032

BAY-606583

Bay-846

Immunotherapy for Oncology

Monoclonal Antibodies for Undisclosed Indication

Monoclonal Antibody to Inhibit CGEN-15001T for Oncology

Monoclonal Antibody to Inhibit CGEN-15022 for Oncology

Monocloncal Antibody Conjugate to Inhibit PDGFR-Beta Receptor for Solid Tumors

Recombinant Protein To Inhibit HER-2 Receptor for Breast Cancer

Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder

Small Molecules to Inhibit Mitogen Activated Protein Kinase Kinase for Oncology

Small Molecules to Inhibit MTH1 for Oncology

Small Molecules to Inhibit Wnt Pathway for Oncology

SMYD-2BAY02

ZK-191784

ZK-216348

Drugs for Endometriosis and Uterine Fibroids

Recombinant Protein for Solid Tumors

Small Molecule to Inhibit Epigenetic Target for Oncology

Small Molecules for Cardiovascular Disease

Small Molecules for Oncology

Small Molecules to Inhibit GLUT1 and GLUT2

Small Molecule for Undisclosed Indication

Bayer AG - Pipeline Analysis

Bayer AG - Pipeline Products by Target

Bayer AG - Pipeline Products by Route of Administration

Bayer AG - Pipeline Products by Molecule Type

Bayer AG - Pipeline Products by Mechanism of Action

Bayer AG - Recent Pipeline Updates

Bayer AG - Dormant Projects

Bayer AG - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Bayer AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Bayer AG, Key Information

Bayer AG, Key Facts

Bayer AG - Pipeline by Indication, 2016

Bayer AG - Pipeline by Stage of Development, 2016

Bayer AG - Monotherapy Products in Pipeline, 2016

Bayer AG - Combination Treatment Modalities in Pipeline, 2016

Bayer AG - Partnered Products in Pipeline, 2016

Bayer AG - Partnered Products/ Combination Treatment Modalities, 2016

Bayer AG - Out-Licensed Products in Pipeline, 2016

Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2016

Bayer AG - Pre-Registration, 2016

Bayer AG - Phase III, 2016

Bayer AG - Phase II, 2016

Bayer AG - Phase I, 2016

Bayer AG - Preclinical, 2016

Bayer AG - Discovery, 2016

Bayer AG - Unknown, 2016

Bayer AG - Pipeline by Target, 2016

Bayer AG - Pipeline by Route of Administration, 2016

Bayer AG - Pipeline by Molecule Type, 2016

Bayer AG - Pipeline Products by Mechanism of Action, 2016

Bayer AG - Recent Pipeline Updates, 2016

Bayer AG - Dormant Developmental Projects,2016

Bayer AG - Discontinued Pipeline Products, 2016

Bayer AG, Subsidiaries

List of Figures

Bayer AG - Pipeline by Top 10 Indication, 2016

Bayer AG - Pipeline by Stage of Development, 2016

Bayer AG - Monotherapy Products in Pipeline, 2016

Bayer AG - Combination Treatment Modalities in Pipeline, 2016

Bayer AG - Partnered Products in Pipeline, 2016

Bayer AG - Out-Licensed Products in Pipeline, 2016

Bayer AG - Pipeline by Top 10 Target, 2016

Bayer AG - Pipeline by Top 10 Route of Administration, 2016

Bayer AG - Pipeline by Top 10 Molecule Type, 2016

Bayer AG - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll